ĐÁNH GIÁ TÍNH AN TOÀN SAU TIÊM TẾ BÀO GỐC TRUNG MÔ KẾT HỢP HUYẾT TƯƠNG GIÀU TIỂU CẦU TỰ THÂN TRÊN BỆNH NHÂN THOÁI HÓA KHỚP GỐI TẠI BỆNH VIỆN BƯU ĐIỆN

Abstract

Objective: This study aimed to evaluate the safety of intra-articular injection therapy using allogeneic umbilical cord–derived mesenchymal stem cells combined with autologous platelet-rich plasma in patients with knee osteoarthritis. Study subjects: Total 21 patients with knee osteoarthritis (42 knees), diagnosed according to the 1991 American College of Rheumatology (ACR) criteria and classified as grade 2–3 based on the Kellgren and Lawrence system, were treated at the Post and Telecommunication Hospital. Methods: A prospective interventional longitudinal study. Results and Conclusion: The number of stem cells injected into each knee joint was 2×10⁷ cells, administered in two separate injections. After 6 months of follow-up, no systemic adverse effects were observed. None of the patients developed joint or periarticular infections, hemarthrosis, or abnormal local osteogenesis during the study period. Four cases (9.5%) of joint effusion were recorded within the first week after injection. However, from week 4 onward, all affected knees showed clinical improvement. These preliminary findings indicate that intra-articular injection of allogeneic umbilical cord–derived mesenchymal stem cells combined with autologous platelet-rich plasma is safe for patients with knee osteoarthritis, with no serious adverse effects detected in this cohort.